Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.43 USD
-0.03 (-0.05%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $64.45 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALPN 64.43 -0.03(-0.05%)
Will ALPN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPN
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
ALPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
StoneCo (STNE) to Post Q4 Earnings: What's in the Offing?
Other News for ALPN
Largest borrow rate increases among liquid names
Alpine Immune Sciences just downgraded at TD Cowen, here's why
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
Biotech Alert: Searches spiking for these stocks today